Isosorbide dinitrate Rx
Generic Name and Formulations:
Isosorbide dinitrate 2.5mg, 5mg; sublingual tabs.
Various generic manufacturers
Indications for Isosorbide dinitrate:
Prophylaxis and treatment (in patients that do not respond to sublingual nitroglycerin) of angina.
2.5–5mg sublingually 15 mins before activity; allow a daily dose-free interval of at least 14hrs.
Concomitant PDEIs (eg, sildenafil, tadalafil, vardenafil), riociguat.
Recent MI. CHF. Hypotension. Volume depletion. Hypertrophic cardiomyopathy. Tolerance may develop. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Severe hypotension with sildenafil. Hypotension potentiated with alcohol, other vasodilators, calcium channel blockers.
Headache, orthostatic hypotension, paradoxical bradycardia.
Sublingual tabs formerly known under the brand names Isordil, Sorbitrate.
Sublingual—contact supplier; Titradose—100
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy